Official Title
Expanded Access to Telisotuzumab Vedotin
Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Available
Individual Patients
Non-small Cell Lung Cancer (NSCLC)

Drug: Telisotuzumab vedotin

Intravenous Infusion
Other Name: ABBV-399

Eligibility Criteria

Inclusion Criteria:

- The participant must not be eligible for a telisotuzumab vedotin clinical trial.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Australia
Germany
Hong Kong
Israel
United States
Locations

Sutter Medical Group /ID# 254816
Sacramento, California, United States

Oncology & Hematology Specialist /ID# 248083
Mountain Lakes, New Jersey, United States

Western Heamatology and Oncology Clinics /ID# 243364
West Perth, Western Australia, Australia

University Hospital Cologne /ID# 254773
Cologne, Germany

Asklepios Fachkliniken Muenchen-Gauting /ID# 259196
Gauting, Germany

Hong Kong United Oncology Centre /ID# 241857
Yau Ma Tei, Hong Kong

The Chaim Sheba Medical Center /ID# 256530
Ramat Gan, Tel-Aviv, Israel

Shaare Zedek Medical Center /ID# 252374
Jerusalem, Israel

Rabin Medical Center /ID# 228611
Petakh Tikva, Israel

Contacts

ABBVIE CALL CENTER
844-663-3742
abbvieclinicaltrials@abbvie.com

ABBVIE INC., Study Director
AbbVie

NCT Number
Keywords
Non-Small Cell Lung Cancer (NSCLC)
Telisotuzumab vedotin
ABBV-399
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
MeSH Terms
Carcinoma, Non-Small-Cell Lung